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Background Chronic spontaneous urticaria (CSU) is characterized by spontaneously 
occurring itchy wheals, angioedema, or both for a period of at least 6 weeks. 
Autoimmunity is thought to be one of the most frequent causes of CSU. Recent studies 
have shown that autohemotherapy can be effective in the treatment of CSU. It has been 
postulated that Autologous Serum Skin Test (ASST)-positive CSU patients may show 
better responses than ASST-negative patients. The mechanisms of action of 
autohemotherapy are unknown, but may include tolerizing or desensitizing effects. Very 
recently, interleukin 24 (IL-24) has been identified as a specific and functional IgE-
autoantigen in CSU. 
Objective To investigate the immunological effects and potential mechanisms of action 
of autohemotherapy, i.e. autologous serum injections, by analyses of the changes in 
serum autoreactivity, as assessed by ASST and basophil histamine release test, and in 
serum concentrations of IgE-anti-IL-24 and IgG-anti-IL-24 in ASST-positive CSU patients. 
Material and methods In total, 66 ASST-positive CSU patients were treated with weekly 
intramuscular injections of autologous serum for 8 weeks and followed up for 12 
additional weeks. Disease activity was assessed with the Urticaria Activity Score (UAS7), 
Dermatology Life Quality Index (DLQI) and the use of on demand antihistamines. The 
ASST was done at baseline, week 9 and week 21. Serum samples obtained at baseline 
and weeks 9, 13 and/or 21 were analysed for concentrations of IgE-anti-IL-24 and IgG-
anti-IL-24 via ELISA and the ability to release histamine in basophils via basophil 
histamine release assay (BHRA). 
Results Therapy with autologous serum markedly reduced CSU disease activity and 
quality of life impairment after 8 and 20 weeks. 28 % (14/50) and 34 % (17/50) of patients 
were turned to ASST-negative in week 9 and week 21, respectively. No significant 
changes in basophil histamine releasing activity were observed. Changes in the ASST 
and BHRA were not linked to the clinical response assessed by the UAS7. Autologous 
serum treatment resulted in a significant decrease of IgE-anti-IL-24 serum concentrations, 
but did not result in changes of IgG-anti-IL-24 serum concentrations. The mean 
concentrations of IgE-anti-IL-24 were correlated with both UAS7 and DLQI at week 21.  
Conclusions Our findings suggest that the immunological effects of autohemotherapy 
include a reduction of skin reactivity to serum factors and concentrations of IgE 
autoantibodies against IL-24, both of which are held to contribute to the pathogenesis of 
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CSU. Further studies are needed to better characterize the relevance of these effects for 
the mechanism of action of autohemotherapy in CSU.  
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2 Zusammenfassung 
Hintergrund: Die chronische spontane Urtikaria (csU) ist charakterisiert durch das 
spontane Auftreten von Quaddeln und/oder Angioödemen über einen Zeitraum von 
mindestens 6 Wochen. Es wird angenommen, dass Autoimmunität eine der häufigsten 
Ursachen für CSU ist. Aktuelle Studienergebnisse konnten aufzeigen, dass eine 
Eigenbluttherapie eine effektive Therapie der csU sein kann. So wurde postuliert, dass 
Autologe Serum Haut-Test- (ASST)-positive csU Patienten möglicherweise besser auf 
eine Eigenbluttherapie ansprechen als ASST-negative. Der Wirkmechanismus einer 
Eigenbluttherapie ist unklar, wobei vermutlich eine Toleranzentwicklung bzw. eine 
Desensitivierung eine Rolle spielen könnte. Erst kürzlich wurde mit Interleukin-24 (IL-24) 
ein häufiges, spezifisches und funktionales IgE-Autoantigen identifiziert. 
Zielstellung: Die vorliegende Studie untersucht die immunologischen Effekte und 
potentiellen Wirkmechanismen einer Eigenbluttherapie mit autologem humanen Serum 
durch die Analyse von Veränderungen des autoreaktiven Profils anhand der 
Veränderungen des ASST und der Histamin-Ausschüttung von Basophilen des Serums 
der csU Patienten. Zusätzlich sollen Serum-Konzentrationen von IgE-anti-IL-24, IgE-anti-
IL-24 und IgG-anti-IL-24 unter der Therapie analysiert werden. 
Material und Methoden: 66 ASST-positive csU Patienten wurden über 8 Wochen mit 
wöchentlichen intramuskulären Injektionen mit autologem Serum behandelt und über 
weitere 12 Wochen verfolgt. Die Krankheitsaktivität mittels Urtikaria Aktivitäts-Score 7 
(UAS7), der Dermatologische Lebensqualität-Index (DLQI) und die Einnahme von 
Anthistaminika wurde über diesen Studienzeitraum erfasst. Der ASST wurde zu 
Therapiebeginn, in Woche 9 und Woche 21 erhoben. Serumproben zu Therapiebeginn, 
in Woche 9, 13 und in Woche 21 wurden mittels ELISA bezüglich der Konzentrationen für 
IgE-anti-IL-24, IgE-anti-IL-24 and IgG-anti-IL-24 sowie der Basophilen Histamin-
Ausschüttung (BHRA) analysiert. 
Ergebnisse: Die autologe Serumtherapie führte zu einer deutlichen Reduktion der 
Krankheitsaktivität und Verbesserung der Lebensqualität nach 8 und 20 Wochen. 28 % 
(14/50) und 34 % (17/50) der Patienten wurden ASST-negativ in Woche 9 und 21. Es 
zeigten sich keine Veränderungen in der Histamin-Ausschüttung der Basophilen. Zudem 
führte die Autologe Serumtherapie zu einer signifikanten Reduktion der IgE-anti-IL-24 
Serumkonzentrationen, wobei sich keine Veränderungen der IgG-anti-IL-24 
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Konzentrationen zeigten. Dabei korrelierten die IgE-anti-IL-24 Konzentrationen mit dem 
UAS7 und DLQI in Woche 21. 
Schlussfolgerung: Die Ergebnisse der Studie zeigen auf, dass eine Eigenbluttherapie 
immunologische Effekte im Sinne einer Reduktion der Hautreaktivität auf Serumfaktoren 
und Abnahme von IgE-Autoantikörpern gegen IL-24 bewirkt, die möglicherweise zur 
Pathogenese der CSU beitragen. Weitere Studien werden benötigt, um die Relevanz 






Urticaria is a common skin disease characterized by the sudden development of pruritic 
wheals, erythematous papules or plaques, with or without angioedema (Figure 3.1). It is 
the fourth most important disease seen by allergists and dermatologists after rhinitis, 
asthma and drug allergy1. Nearly 20 % of the population will suffer from urticaria at least 
once in their lifetime2. According to the frequency and duration of symptoms, urticaria can 
be classified into acute and chronic urticaria3. Chronic urticaria is defined as occurrence 
of the symptoms for more than 6 weeks and can be divided into the chronic spontaneous 
form (CSU) and the chronic inducible form (CINDU). 
Figure 3.1 Urticaria wheals and angioedema 
3.1.1 Epidemiology and prevalence 
Urticaria occurs in both adults and children with a prevalence from 0.11 % to 0.6 %4. 
Acute urticaria accounts for up to 16-20 % of all urticaria patients and occurs more widely 
in infants and young children5,6. The incidence of CSU and other chronic forms of urticaria 
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is up to 1 % in most European countries7,8 and it appears to be more common in adults, 
with females affected twice as often as males1,6,7. CSU is thought to affect at least 0.1 % 
of the population9. The chronic inducible forms including physical urticaria and other types 
of inducible urticaria are not that common. Physical urticaria comprises up to 25 % 
amongst cases of chronic urticaria10. 
3.1.2 Classifications 
3.1.2.1 Acute urticaria 
Acute urticaria (AU) is defined as the occurrence of wheals for less than 6 weeks. In up 
to 50 % of AU patients, no cause can be identified11. Other attacks may be associated 
with food, drugs, inhalants and infections. The attack of acute urticaria may co-occur with 
or without angioedema, and the wheals come in different sizes and shapes. 
3.1.2.2 Chronic urticaria 
Chronic urticaria can be classified into chronic spontaneous urticaria (no specific eliciting 
factor involved) and chronic inducible urticaria (specific eliciting factor involved)6(Table 
3.1). 
Table 3.1 Classification of chronic urticaria 
Chronic Urticaria Subtypes 
Chronic spontaneous urticaria 
(CSU) 
Chronic inducible urticaria 
(CINDU) 






Delayed pressure urticaria 
Aquagenic urticaria 
• Chronic spontaneous urticaria (CSU) 
Chronic spontaneous urticaria (CSU) is characterized by the spontaneous occurrence of 
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itching and short-lived wheals with or without angioedema lasting for more than 6 
weeks6,12. Although CSU is a non-life-threatening disease, patients often have a poor 
quality of life and the burden of disease impacts the patients at work or school13. In up to 
90 % of the cases, the cause of the disease could not be figured out by routine clinical 
practice6,14. Nowadays, autoimmunity is discussed as playing a critical role in the 
pathogenesis of CSU (discussed in the next chapter). 
• Chronic inducible urticaria (CINDU) 
(i) Symptomatic dermographism 
Symptomatic dermographism, also known as factitial urticaria, is defined as the 
appearance of a wheal and flare reaction shortly (within seconds to few minutes) after 
applying shearing force to the skin15. It can be confirmed by stroking the skin with a blunt-
pointed object, which causes an immediate linear red itching wheal response5.  
(ii) Cold urticaria 
Acquired cold urticaria is characterized by a localized or diffuse eruption of wheals after 
the exposure of the skin to cold objects, air or liquids16. The ice cube test is a simple test 
to diagnose cold urticaria by stimulating the skin on the volar surface of the forearm for 5 
min with an ice cube17. If patients develop wheals after rewarming for 5-10 min, the test 
is considered as positive.  
(iii) Cholinergic urticaria  
Cholinergic urticaria (CholU), a subgroup of chronic inducible urticaria is characterized by 
pinpoint-sized (surrounded by macular erythema) and highly pruritic wheals that are 
provoked by elevation of the body’s core temperature such as sweating in exercise, spicy 
foods, strongly emotional stress, and hot baths18.  
(iv) Solar urticaria  
Solar urticaria is a very rare photodermatosis triggered by light exposure within minutes 
to a few hours. The disease is defined as itching, wheals and erythema induced by 
ultraviolet, visible, or even infrared radiation19,20. Phototesting/photoprovocation is used 
to confirm the diagnosis.  
(v) Heat urticaria 
Heat urticaria is recognized by the formation of wheals and itchy erythema after direct 
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contact with heat (objects, liquids, air). A diagnosis is made by a skin provocation test 
such as a hand water bath of 40℃ water for 10 min until an urticarial response is observed.  
(vi) Vibratory urticaria 
Vibratory urticaria is a rare form of physical urticaria characterized by pruritus and swelling 
at the site of skin under exposure to vibration including motorcycling, playing the trumpet 
or using electric drills or lawnmowers6,21.  
(vii) Delayed pressure urticaria 
Delayed pressure urticaria (DPU) is characterized by the development of erythematous 
wheals after sustained pressure is applied to the skin. Compared to other subtypes of 
urticaria, DPU patients usually suffer from rather burning and severe pain20.  
(viii) Aquagenic urticaria 
Aquagenic urticaria was first described by Shelley et al. (1964)22 and is defined as a 
distinctive folliculopapular urticaria induced by contact with water at any temperature6.  
 
The etiology of the different CINDUs is widely unknown, but autoimmune and/or 
autoallergic mechanisms were thought to play a role in the pathogenesis of CINDU. 
3.1.3 Etiology, trigger factors and pathogenesis of CSU 
3.1.3.1 Etiology 
The etiology of urticaria is unknown, and most reviews failed to identify a cause in the 
majority of CSU patients. However, some hypotheses can be given, such as autoimmunity, 
thyroid disorder, malignancy and hereditary disorders23,24. Recent studies suggested that 
the incidence of CSU was higher among first-degree relatives25 and the association with 
human leukocyte antigen class II proved a genetic background of this skin disease26. 
3.1.3.2 Trigger factors  
• Medications and food 
Pseudo-allergy (non-allergic hypersensitivity reactions) against foods, food additives or 
drugs (such as non-steroidal anti-inflammatory drugs (NSAIDs)) has been described to 
trigger or aggravate preexistent CSU6. Type-I reactions to food are a rare cause of CSU, 
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e.g. younger children showed symptoms after having cow’s milk, eggs and seafood. For 
adults, the most common foods were seafood and nuts27,28. 
• Infection 
The causal relationship between urticaria and infectious disease has been discussed for 
more than 100 years29. Several chronic persistent bacterial infections (helicobacter pylori, 
streptococcus, staphylococcus, mycoplasma pneumonia and brucella)30, viral infections 
(cytomegalovirus, parvovirus B19, norovirus, hepatitis B virus)31, parasitic infections 
(ascaris, filarial, schistosoma, toxocara)32 or fungal infections (candida albicans)33 were 
suspected to trigger urticarial symptoms in patients. 
• Psychological factors  
Psychological factors were studied as critical triggers in patients with urticaria. Most 
reports suggested that anxiety, emotional distress, severe depression and anger played 
a role in worsening CSU.34,35 
3.1.3.3 Pathogenesis 
The cellular effects, inflammatory mediators and autoimmunity are all crucial to the 
pathogenesis of CSU. But none of the theories have been conclusively established26,36. 
• Skin histopathology  
Skin mast cells degranulate in the dermis and cellular perivascular infiltrates such as 
neutrophils, eosinophils and lymphocytes were found to be the major components of 
histopathology in urticaria37,38. The histology of CSU was characterized as a non-
necrotizing perivascular infiltrate composed of monocytes and CD4+ T lymphocytes39. 
The clinical symptoms and the leukocyte infiltrate shown in chronic urticaria are similar to 
the late phase of allergen-induced reactions. However, compared to allergen late phase, 
chronic urticaria lesions have a Th0 rather than Th2 cytokine profile38. Hermes et al. 
(1999)40 demonstrated that endothelial cells increased expression of tumor necrosis 
factor α and interleukin 3 in lesional and non-lesional skin of chronic urticaria patients. 
• Cellular effects  
Degranulation of mast cells and basophils is a main event in urticaria38 and the levels of 
histamine in skin biopsied are elevated41,42. Some findings reported an increase in mast 
cell numbers, which underlined the complex nature of the pathogenesis of urticaria6. 
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However, some studies reported that no difference of mast cell numbers was observed 
in lesional, non-lesional or healthy skin43. The elevation of histamine levels42 might be 
associated with either increased quantitative release of histamine from skin mast cells or 
blood basophil infiltration of CSU skin tissues44.	 Blood basophils have also been 
investigated for decades in CSU, especially when Greaves et al. (1974)45 and Kern et.al. 
(1976)46 identified a reduction in total available histamine-release ability after IgE-
receptor activation. Blood basophils IgE receptor responses of patients with CSU have 
been segregated into two basophil phenotypes: CSU responders and CSU non-
responders. These two phenotypes are stable in active disease and have different 
expression in some features. In contrast to the responders, the non-responder basophils 
do not degranulate to ex vivo IgE receptor activation and possess elevated 
concentrations of the IgE receptor regulating inhibitory phosphatases, SH2 domain-
containing inositol 5-phosphatase (SHIP)-1 and SHIP-2.  
• Autoimmune mechanisms 
Autoimmunity is thought to be one of the most frequent causes of CSU. The autoimmune 
theory was first originated from the high correlation between the presence of autoimmune 
serum factors and thyroid autoimmunity. The occurrence of thyroid autoantibodies and 
thyroid dysfunction in CSU patients is two times higher than that of the general 
population47,48. In the 1980s, this theory was developed based on an in vivo skin test 
(autologous serum skin test, ASST), in which 58 % (7/12) of CSU patients had wheal and 
flare reactions at the site of intradermal injections of their own serum within 30 min49. Also, 
around 30 - 40 % of (overlapping) CSU patients showed circulating IgG autoantibodies 
to either IgE or the α subunit of the high affinity IgE receptor that could induce mast cell 
and basophil degranulation36.This autologous serum skin test (ASST) has been proven 
to be one of the most useful screening tests for autoimmune urticaria6,50 and the 
circulating histamine-releasing factors are responsible for the wheal and flare symptoms 
in ASST-positive patients51. Interestingly, ASST-positive patients have more associated 
systemic symptoms and autoimmune conditions than ASST-negative patients52. In 
addition, a study demonstrated CSU serum could induce histamine release from 
basophils of healthy donors because of the IgG autoantibodies	targeting the Fc part of 
IgE53. This activity was termed basophil histamine release assay (BHRA). 	
Two types of autoimmune reactions (IgE to autoallergens and IgG autoantibodies to IgE 
or its receptor, respectively) have been claimed to be relevant to autoimmune CSU 
	 11	
patients so far54 (Figure 3.2). Rosman et al. (1962)55 first described that CSU could be 
caused by a hypersensitivity type I reaction. In this reaction, mast cells and basophils can 
release histamine and other proinflammatory mediators after IgE molecules crosslink on 
their surfaces with (auto) antigens. There is evidence that autoreactive CSU patients have 
much higher concentrations of IgE autoantibodies against double-stranded DNA and 
thyroid antigens such as thyroid peroxidase / thyroglobulin than normal subjects48,56,57. In 
the type II reaction, 30 - 50 % of CSU patients express autoantibodies that can induce 
degranulation of mast cells and basophils58 including circulating IgG autoantibodies 
directed against the high-affinity receptor for IgE (IgG-anti-FcɛRI) or the IgE molecule 
(IgG-anti-IgE)59-61.   
 
Figure 3.2 Proposed pathomechanisms of autoimmune CSU: Two types of proposed 
autoimmune reactions 
3.1.3.4 Interleukin 24 (IL-24) 
Interleukin 24 (IL-24) is a member of the interleukin 10 family of cytokines. It forms signals 
upon linking to one of two heterodimeric receptors: IL-20R1/IL-20R2 and IL-22R1/IL-
20R262,63. IL-24 was first known as melanoma differentiation-associated 7 (mda-7) 
because of its tumor-suppressing activity in healthy melanocytes by multiple 
pathways64,65. IL-24 can selectively control and inhibit the apoptosis, proliferation, 
invasion and metastasis of cancer cells via binding to its receptors, then rapidly activate 
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signal transducers and activators of transcription 1 (STAT-1) and STAT-3 transcription 
factors. IL-24 can be secreted by monocytes, macrophages, keratinocytes and activated 
T helper 2 cells. The major target tissues of IL-24 are non-haematopoietic tissues, e. g., 
skin, lung and reproductive tissues66,67. IL-24 is expressed in the human immune system, 
including the thymus, spleen and peripheral blood leukocytes. It plays important roles in 
wound healing, arthritis and cancer. Furthermore, IL-24 is also shown at increased levels 
in psoriasis64,66. Very recently, IL-24 was identified as a common, specific and functional 
autoantigen of IgE autoantibodies in CSU. Interestingly, IgE-anti-IL-24 was detected in all 
patients with CSU, but it was undetectable in idiopathic anaphylaxis patients or healthy 
subjects. Furthermore, the concentrations of IgE-anti-IL-24 were found to be associated 
with the urticaria disease activity68. 
3.1.4 Management of chronic spontaneous urticaria 
3.1.4.1 Diagnostic approach 
• Confirm a diagnosis of CSU 
The lesions of CSU may vary in shape and size, present as itchy raised wheals 
surrounded by an erythematous base and central pallor (Figure 3.1). Diagnosis can be 
confirmed by a detailed history such as signs and symptoms, aggravating factors, and 
past medical history. Normally, laboratory investigations are not required for diagnosis of 
CSU. The EAACI/GA²LEN/EDF/WAO guideline recommend physical exams, full blood 
count (FBC), C-reactive protein (CRP) and further individual tests such as antinuclear 
antibodies (ANA) to identify underlying causes3.	 	
• Assess the disease activity in CSU 
The guideline suggests using the urticaria activity score (UAS) to assess disease activity6. 
Daily urticaria activity scores (UAS, range 0-6) are calculated as the sum of wheal and 
itch scores as follows (Table 3.2). The weekly UAS (UAS7, range 0-42) is calculated by 




Table 3.2 The UAS7 for assessing disease activity in CSU 
UAS7 score Wheals Pruritus 
0 No wheals None 
1 < 20 wheals Mild itch 
(Present but not annoying) 
2 20-50 wheals Moderate itch 
(Troublesome but does not 
interfere with normal daily 
activity or sleep) 
3 >50 wheals Severe itch 
(Sufficiently troublesome to 
interfere with normal daily 
activity or sleep) 
3.1.4.2 Treatment 
The first therapeutic option is to avoid eliciting factors such as food and NSAIDs. The 
main goal of therapy in CSU is to achieve complete symptom control. Evidence-based 
guidelines support that the most effective, first-line treatment for CSU are non-sedating 
second generation antihistamines, since the older first-generation sedating 
antihistamines have side effects on central nervous system3. A number of non-sedating 
antihistamines were shown to be effective in clinical studies, e. g., cetirizine, 
desloratadine, fexofenadine, levocetirizine, loratadine, ebastine, rupatadine and 
bilastine6,69-71. Considering that up to 50 % of patients72 still suffer from symptoms with 
the use of standard-dosed non-sedating agents, an up-dosing up to the four-fold dose is 
recommended as second-line treatment73. Around two thirds of non-responders to 
standard doses were shown to benefit from antihistamine up-dosing74. Although this 
treatment is off-label, antihistamine updosing has not been associated with severe 
adverse events or safety concerns75. 
Omalizumab, a humanized anti-IgE antibody has recently been shown to be very effective 
and safe in the treatment of CSU76,77. It is approved for CSU, suitable for long-term 
treatment and can markedly improve the patients’ quality of life. Maurer showed that 
omalizumab diminished clinical symptoms in CSU patients who had no response to 
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approved doses of H1-antihistamine77. The guidelines recommend adding omalizumab 
as the third-line treatment in CSU patients unresponsive to second-generation H1-
antihistamines. Ciclosporin A has been used for many years in refractory CSU and is 
known to inhibit mast cell mediator release78. In combination with second-generation H1 
antihistamines it has exhibited beneficial effects in patients with severe disease refractory 
to any dose of antihistamines79. However, this drug is off-label for urticaria and may be 
associated with a number of side effects such as hypertension, hypertrichosis and 
headache. In summary, the guidelines suggest that omalizumab should be tried before 
ciclosporin A6. 
3.2 Autohemotherapy for chronic spontaneous urticaria 
Autohemotherapy, i.e., repeated intramuscular or intravenous injections of autologous 
serum or autologous whole blood, has been used for over 150 years. Autohemotherapy 
is not a standard treatment of CSU, but it has been reported to be effective in patients 
with chronic urticaria in clinical trials and real-life practice. There are different forms of 
autohemotherapy used in urticaria treatment, such as autologous whole blood vs. 
autologous serum injections and intramuscular vs. subcutaneous injections. Godse et al. 
80 reported that subcutaneous autologous serum therapy was effective and better than 
intramuscular applications in the treatment of CSU. Panchami et al. (2014)81 confirmed 
that autologous serum therapy was a useful adjunct in the treatment of CSU. They 
showed that autohemotherapy reduced the intake of antihistamines and improved the 
quality of life. More recently, Staubach et al. 82 and Elazab et al. 83 reported that 
autohemotherapy is very effective in autoimmune CSU patients, with ASST-positive 
patients showing a better clinical response than ASST-negative patients in both studies. 
In CSU treatment, most studies applied one injection per week for a period of 8-10 weeks. 
Although few studies reported an increase of infection risks e.g., hepatitis C84,85, it 
appears to be safe to perform autohemotherapy using a direct withdrawal-and-injection 
approach without any procedure in between. Since the autohemotherapy procedure is 
safe and simple to perform and inexpensive, it is highly recommended for less developed 
countries. 
The mechanism of action of autohemotherapy is still not well understood. Several lines 
of evidence point to the effects on immune mechanisms: Bocci et al. (1994)86 claimed 
that “autohemotherapy may represent a physical stimulation for reprogramming the 
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immune system”. They suggested the effects of autohemotherapy were linked to the 
apoptosis of autocytotoxic T lymphocytes caused by IFNγ or other immunosuppressive 
factors such as IL-10, TGFβ antagonists and eicosanoids. In contrast, Sheikhi et al. 
(2014)87 suggested a potential mechanism where the induced anti-idiotype antibodies 
could react against IgE autoantibodies and subsequently block IgE autoantibodies to 
bind with their high affinity receptors (FcεRI) of mast cells or basophils. Interestingly, 
some clinical studies, but not all, suggested that serum autoreactivity in CSU patients 
had a high concordance with the response to autohemotherapy. For example, Staubach 
et al. (2006)82 proposed that ASST-positive CSU patients, but not ASST-negative CSU 
patients, benefited greatly from autologous whole blood therapies due to the induction 
of tolerance to circulating histamine-releasing factors. Zhang et al. (2014)88 have 
suggested that the mechanism of action of autohemotherapy is possibly related to the 
down-regulation of IL-4 and IgE in patients. Based on these reports, we investigated the 
effects of autohemotherapy in ASST-positive patients with CSU on two distinct 





4 Aim of the study 
Recent small studies and case reports have shown that patients with CSU can benefit 
from autohemotherapy. However, the treatment regimes were not standardized and 
results from larger patient cohorts are lacking. Also, the mechanism of action of this 
therapeutic option remains elusive so far. We hypothesize that autohemotherapy is 
effective and safe in treating patients with autoimmune CSU. Thus, we aim to assess 
whether autologous serum injections decrease the disease activity in CSU and can even 
cure a proportion of patients of their condition. We postulate that the therapeutic effects 
of autohemotherapy in CSU are due to tolerization/desensitization processes induced by 
the injections of autologous serum. To investigate the effects of autohemotherapy in CSU 
patients, we will: 
• Assess serum reactivity before, during and after eight weeks of autohemotherapy 
by autologous serum skin tests and basophil histamine release assay 
• Monitor the concentrations of IgE (and IgG) against Interleukin 24 
• Assess changes in serum autoreactivity and IgE-anti-IL-24 concentrations for their 
clinical relevance and correlate them with changes in clinical outcome parameters, 
i.e. the weekly urticaria activity score (UAS7), the on demand use of antihistamines, 
and quality of life (DLQI) 





5.1 Trial design and selection of patients 
This was an observational study during the period from September 2010 to December 
2013, which intended to include all available prospective CSU patients with a known 
positive autologous serum skin test who had received autologous serum therapy. As a 
multicenter project it was attended by the GA2LEN Urticaria Centers of Reference and 
Excellence in Berlin, Germany and Istanbul, Turkey as well as the Nashik Urticaria Clinic, 
India. Patients were recruited by all participating centers.  
The study on autohemotherapy is a pilot study in 66 patients. The sample size is 
considered sufficient to adequately investigate the objectives of this exploratory study. 
This assumption is based on the investigator’s experience with minor pilot studies about 
the treatment of urticaria89–93.	With the unknown variability of the treatment effect in this 
population, statistical power considerations are unwarranted in principle. Formally, by 
assuming an effect size of 0.20 for changes in UAS7, 134 patients will be needed for the 
analysis to reach a power of 80% with a level of significance of 0.05 (one sample size t-
test). With an effect size of 0.30, there will be 74 patients required. With an effect size of 
0.50, the minimum patient number should be 28 for the analysis, with an effect size of 
0.80, the number of patients needed will be only 12 (calculated by G*Power 3.1). 
 
For selection of patients, the following criteria had to be fulfilled: 
Inclusion criteria:  
1  Male and female outpatients, aged between 18 and 75 years  
2  Approved diagnosis of chronic spontaneous urticaria (duration > 6 weeks) with a 
positive autologous serum skin test (ASST-positive)  
3  UAS 7> 6 in baseline week  
4  History of beneficial effects of antihistaminic treatment  
5  Signed and dated informed consent of the patient before the start of specific 
protocol procedures  
6  Patients must be able and willing to record symptom scores and to document them 
in diaries.  
7  Ability to understand the scope and nature of the trial and to understand and write 
and fill in the patient diary.  
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Exclusion criteria: 
1. Chronic severe diseases, especially those affecting the immune system, except 
autoimmune chronic urticaria  
2. Acute urticaria (history of urticaria less than 6 weeks) or mainly physical urticaria  
3. Any pathologic alterations in the area of autologous serum application which may 
interfere with intramuscular injections  
4. History or presence of epilepsy, significant neurological disorders, cerebrovascular 
attacks or ischemia.  
5. Therapy with anticoagulants, e.g. warfarin or phenprocoumon  
6. Constant therapy with acetylsalicylic acid  
7. Presence of active cancer which requires chemotherapy or radiation therapy  
8. Presence of alcohol abuse or drug addiction  
9. Permanent use of oral corticosteroids or other immunosuppressants / 
immunomodulators within 3 weeks prior to start or at any time during the study  
10. Emergency use of oral corticosteroids >12 times in the last year  
11. Pregnancy or breast-feeding  
12. Significant changes in naturopathic or complementary treatments that may affect 
chronic urticaria such as special diets, fasting, microbiological therapies or 
acupuncture within 6 weeks prior to start or at any time during the study. 
Treatment and data collection schedule: 
Table 5.1 Schedule of treatment 
 
All patients provided written and oral consent and the study was approved by the ethics 
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committee of the Charité-Universitätsmedizin Berlin. 
5.2 Assessment of disease activity and impact 
Disease activity assessment was based on the weekly Urticaria Activity Score (UAS7) 
and the use of on-demand antihistamines (AH-demand). Disease impact on quality of 
life was assessed with the Dermatology Life Quality Index (DLQI). UAS7 scores, AH-
demand data and DLQI values were obtained by use of patient diary documentation. 
The schedules of visit and treatment are shown in Table 5.1.  
5.2.1 Calculation of UAS7 
Patients recorded the number of wheals and the intensity of pruritus daily during weeks 
0-8, 12, and 20. The weekly urticaria activity scores (UAS7) were calculated as the sum 
of wheal and itch scores over 7 days as shown in Table 3.2. If less than 7 days are 
available for rating at a visit, missing days will be replaced by the average of the daily 
values available from the diary (Table A.1, Appendix). 
Response to the treatment was defined by a reduction of UAS7 compared to week 0. 
“Complete response” was defined as a reduction of UAS7 equal to or more than 90 %, 
“partial response” as a reduction of between 30 - 90% and “non response” as equal to or 
less than a 30 % reduction in UAS7. 
5.2.2 Calculation of on-demand use of antihistamines 
The antihistamine demand (AH-demand) was determined weekly. During weeks 0-8, 12, 
and 20, antihistamines should be administered only when needed, at all other time points 
patients were free to use antihistamines either on-demand or as prophylaxis. The weekly 
AH-demand score was calculated as the sum of all antihistamine tablets (one point per 
tablet) used per week. Patients were advised to use cetirizine first line. However, if 
cetirizine was not efficient or tolerated, other antihistamines were permitted. 
Antihistamines were not allowed within three days before the ASST (Table 5.1 and A.1, 
Appendix). 
5.2.3 Calculation of DLQI 
The quality of life of patients was investigated by the Dermatology Life Quality index 
(DLQI). The DLQI was developed in 1994 by Finlay and Kahn as quality of life 
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questionnaire for patients with dermatological disease94,95. The DLQI consists of 10 
questions across six domains: symptoms/feelings, daily activities, leisure, work/school, 
personal relationships and treatment. Each question is scored from ‘very much’ (score = 
3) to ‘not at all’ (0), and an overall score (0-30) is calculated by totaling the individual 
domain scores. Higher scores indicate higher quality of life impairment. 
The DLQI was applied in weeks 1, 9, 13 and 21. A minimal clinically important difference 
(MCID) of 3-4 points has been estimated to be meaningful for the DLQI in patients with 
CSU96. The MCID is the minimum change considered important by the patient and 
mandating a change in management. The proportion of patients whose change in the 
total DLQI score from baseline reached an MCID of ≥ 4 was also assessed at week 9, 13 
and 21 (Table 5.1 and Table A.2, Appendix). 
5.3 Autologous serum skin test 
This very simple and quick test is used as a screening instrument to identify the presence 
of circulating histamine-releasing factors in CSU patients. In each patient, 2ml of venous 
blood was drawn from the cubital vein and the serum was separated by centrifuge at 1300 
rpm for 15 min at room temperature. 50 μl of normal saline (negative control), histamine 
(10 μg/mL) (positive control) and serum, serum diluted (saline) 1:1 and serum diluted 1:10 
were injected intradermally 3 to 5 cm apart into the volar forearm of the same patient 
(Figure 5.1). The test area should be free of lesions. The maximum vertical (d1) and 
horizontal (d2) diameters of the wheals were measured with a transparent ruler after 10 
min. The average diameter (D) was calculated [D = (d1 + d2) / 2] (Figure 5.2). A positive 
test was defined as a serum-induced wheal response at any concentration with an 
average diameter of more than 2 mm than the negative control. ASST was performed at 
week 0, 9 and 21, with no antihistamine intake three days prior to testing (Table 5.1). 
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Figure 5.1 ASST-positive CSU patient: The ASST is positive with the injections of 
undiluted serum, but remained negative at serum diluted with 1:1 and 1:10 with saline. 
 
 
Figure 5.2 Measure and calculate the wheals 
5.4 Autologous serum injections 
Venous blood was drawn from the cubital vein and the serum was separated by centrifuge 
at 1300 rpm for 15 min at room temperature. The obtained autologous serum was 
reinjected into the gluteal muscle of the patient immediately without any further 
manipulation at week 1 to week 8. The volume of the first injection was 0.025 ml / kgBW 
(with a maximum of 2.5ml in total); in all further treatments 0.05 ml / kgBW (with a 
maximum of 5 ml in total) per injection was applied. Altogether, there were eight injections 
at alternating sides, once a week over eight weeks. (Table 5.1 and Figure 5.3). 
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Figure 5.3 Timetable for taking blood 
5.5 Blood samples 
Blood samples for ELISA and BHRA were taken at time points 0, 9, 13 and 21 (Table 5.1 
and Figure 5.3). Samples were centrifuged at 1300g for 15 minutes at room temperature 
to separate serum and plasma. Serum and plasma were portioned in 500 µl Eppendorf 
microtubes and stored at -80 °C. 
5.6 Outcome measures 
Reduction of disease activity is assessed by UAS7 including number of wheals and 
intensity of itch (week 0 vs. week 8). UAS7 was calculated using the data documented in 
the patient´s diary (Table 5.1 and Table A.1, Appendix). 
Long-term (week 12 and 20, resp. vs. week 0) efficacy in reduction of urticaria symptoms 
(UAS7, wheal number and size, pruritus duration), quality of life, autologous serum skin 
test reaction (size and duration), and reduction of antihistamine demand were assessed 
by patient and investigator (Table 5.1 and Table A.1, Appendix). 
5.7 Measurements of autoantibodies against IL-24 
IgE-anti-IL-24 serum concentrations were assessed by a site-directed IgE capture ELISA 
as reported recently68. In brief, 16 μg of anti-IgE antibody (MHE18, Biolegend) was 
dispensed in 10 ml Coating Buffer (0.1 M carbonate at pH = 9, Sigma) to make a coating 
solution. Each well of a black Maxisorb plate (Thermofisher) was coated overnight at 4 °C 
with 25 µl of the coating solution. After blocking with 2 % HSA in TBS-Tween overnight at 
4 °C, 25 μl of serum was added into each well and incubated at 4 °C overnight. After the 
removal of unbound protein from the plate by three washing steps with TBS-T and water, 
respectively, 25 μl of the antigen-solution (20 μl IL-24-BHHCT-Eu per 10 ml 50 mM Tris 
buffer pH = 8) per well was added and the plate was incubated at 4 °C for 2 h. After ten 
washing steps, 25 μl DELFIA enhancer solution (Perkin Elmer, Waltham, USA) was added 
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to each well and the plate was incubated for 5 min at room temperature. Finally, the plates 
were measured in a Victor V reader (Perkin Elmer) with standard Europium settings.  
For the measurement of IgG-anti-IL-24, 16 μg of anti-IgG antibody (anti-human IgG Fc, 
Biolegend) were dispensed in 10 ml Coating Buffer to make a coating solution.  
5.8 Basophil histamine release assay 
The serum induced histamine release method aims at detecting autoantibodies in patient 
sera directed against both the free IgE receptors and the cell bound IgE by the use of 
blood bank buffy coat donor blood containing 1-2 % basophils. An optimal histamine 
release response is obtained by partial removal of basophil bound IgE by the stripping 
procedure described below. As the cell response varies between different donors, four 
blood bank buffy coats were collected from the blood bank the day before performing the 
test. They must origin from blood that has been drawn and fractionated within the same 
day. The buffy coats were mixed with equal volumes of RPMI. IL-3 in a final concentration 
of 1 ng / mL was added and the samples were stored overnight at 2-8 °C. The next day 
the buffy coats were centrifuged to remove plasma and RPMI. Thereafter the samples 
were washed with physiological saline and subsequently exposed to low pH using a 
stripping buffer, pH = 3.6 from RefLab, Denmark, Copenhagen to partially remove IgE 
from the basophils. Finally, the IgE-stripped samples were resuspended in Pipes buffer 
from RefLab before incubation with patient sera. Each serum was tested at a dilution of 
20 % and 10 %. Total histamine content was determined after lysis of cells with 7 % 
HClO4.  
The following standard controls (pools) were included in each testing and the histamine 
release criteria stated below were fulfilled to include the results: 
Pool negative: sera collected from healthy volunteers. Histamine release < 5 %.  
Pool I: sera from CSU patients. Histamine release between 60 % and 80 %.  
Pool II: sera from CSU patients. Histamine release between 30 % and 50 %.  
Pool III: sera from CSU patients. Histamine release between 20 % and 30 %.  
Pool Positive: Anti-IgE from KPL, USA, 4 ng / mL. Histamine release > 30 %. 
Next, patient sera and stripped buffy coat cells were incubated in a total volume of 100 
µL for 60 minutes at 37 ˚C. After centrifugation, 25 µL supernatants were transferred to 
glass fiber coated microtiter plates RLA210 and histamine was measured according to 
RefLab instructions. A triplicate histamine determination of each sample was performed. 
Assay variation was < 7 %. Assay sensitivity was 5 ng histamine / mL. The release of 
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histamine in cell supernatants was expressed as the percentage of total histamine 
content from lysed donor cells. A positive BHRA is defined as 16.5 % above the 
spontaneous histamine release97. 
5.9 Assessment of the outcome parameters and schedule 
In summary, for UAS7 and AH-demand, the results of measurements were determined at 
week 0 (at baseline), 8 (immediately after end of treatment), 12 (4 weeks after the end of 
treatment) and 20 (12 weeks after end of treatment). The measurements for DLQI were 
determined at week 1, 9, 13, and 21. ASST was assessed at baseline (week 0) and 
additionally in the weeks 9 and 21 (Table 5.1). 
5.10 Statistical Analysis 
Statistical analysis of the data was performed using GraphPad Prism 6.0 and IBM SPSS 
statistics 23 software. Sample size calculation was performed by G*Power 3.1. Data were 
analysed by calculating values for the mean and standard error of the mean (= SEM), 
and mean or standard deviation (= SD). Two related paired non-parametric data were 
compared using the Wilcoxon singed-rank test. Two independent data were compared 
using Mann Whitney U test. Paired and categorical data (e.g. data from the same patients 
obtained at different time points) were compared using the McNemar test. One or more 
categorical data were compared using the Chi-squared test. Correlations were 
determined by the Spearman test. In the statistical tests, a p-value ≤ 0.05 was considered 




6.1 Study participants and availability of samples and data  
We included 66 CSU patients in the study. Of the 66 patients, 21 were from Berlin, 33 
from Istanbul, and 12 from Nashik. Based on the fact that this was an observational study, 
serum samples and clinical data were not available from all time points for all participants. 
Data shown are from all patients with available data at the specific timepoints. For 
example, for analyses of disease activity scores UAS7, there were only 46 complete data 
sets available for each timepoint to compare. 
Since this was a multiple centers study, 10 patients’ blood samples were damaged during 
transportation and 41 patients’ sera were missing from certain study centers or certain 
timepoints. So there were only 15 patients’ serum samples available for all timepoints for 
the analysis of IgE-anti-IL-24 and IgG-anti-IL-24 antibodies.	
6.2 Effects of autohemotherapy in ASST-positive CSU patients 
6.2.1 Changes in disease activity 
Autologous serum therapy markedly reduced the mean ± SEM CSU disease activity as 
assessed by UAS7 from 23.3 ± 1.2 before treatment to 14.8 ± 1.7 at the end of the 8-
week treatment period (~ 36 %, p ≤ 0.0001, Figure 6.1 a+b). Disease activity was first 
significantly reduced, to 17.9 ± 1.4, after 2 weeks of treatment (~ 23 %, p ≤ 0.0001). UAS7 
values continued to decrease after the end of treatment, to 12.8 ± 1.6 (~ 45 %, p ≤ 0.0001) 
and 12.6 ± 1.8 (~ 46 %, p ≤ 0.0001) at week 12 and 20, respectively (Figure 6.1 a+b). 
Since the UAS7 values showed a skewed distribution, Figure c demonstrates the Mode 
value of different time points, which also means that most patients decrease the disease 




Figure 6.1 Effects of autologous serum therapy on disease activity in patients with CSU 
and a positive ASST. UAS7 scores are shown for each patient and displayed as mean 
and standard error of the mean (SEM) (Figure a+b) and mode value (Figure c). **** p 
≤0.0001 (Wilcoxon signed-rank test) compared to week 0; UAS7 = Weekly Urticaria 
Activity Score. N = 46. 
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6.2.2 Changes in antihistamine demand 
Autologous serum therapy significantly reduced the antihistamine demand (AH-demand) 
in autoimmune CSU patients. Figure 6.2 indicates that the use of on-demand 
antihistamine treatment was significantly decreased in week 8 after the treatment (from 
2.9 ± 0.6 to 1.5 ± 0.4 tablets per week, p ≤ 0.05) and continued to decrease thereafter, to 
1.4 ± 0.4 tablets per week (p ≤ 0.01, in week 20). 
 
 
Figure 6.2 Effects of autologous serum therapy on the use of on-demand antihistamine 
medication are shown for each patient and displayed as mean and standard error of the 
mean (SEM). * p ≤ 0.05, ** p ≤ 0.01(Wilcoxon signed-rank test) compared to week 0; N = 
49.  
6.2.3 Changes in quality of life 
Treatment with autologous serum lead to a long-term increase in the quality of life 
assessed by the DLQI (Figure 6.3a). Quality of life was significantly improved from 8.8 ± 
1.2 (at baseline, corresponding to moderate impairment) to 6.3 ± 1.1 (at week 9, 
corresponding to moderate impairment, p ≤ 0.05), 6.0 ± 1.2 (at week 13, corresponding 
to moderate impairment, p ≤ 0.01) and 5.1 ± 1.1 (at week 20, corresponding to mild 
impairment, p ≤ 0.001) after the start of treatment. Furthermore, the results demonstrated 
that the quality of life even continued to improve after 12 weeks in the follow-up period.  
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Figure 6.3 Effects of autologous serum therapy on the DLQI are shown for each patient 
and displayed as mean and standard error of the mean (SEM) (Figure a) and mode value 
(Figure b). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤0.001 (Wilcoxon signed-rank test) compared to 
week 0; DLQI = Dermatology Life Quality Index. N = 33. 
 
After an 8-week therapy with autologous serum, the proportion of patients that reached 
an MCID of ≥ 4 in total DLQI scores was 35 % (15/43) compared to baseline. The 
percentage increased steadily to 41 % (19/46) in week 13 and 47 % (20/43) in week 21. 
However, there was no significant difference between week 9, week 13 and week 21. 
(McNemar test, p > 0.05) (Figure 6.4).  
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Figure 6.4 Distribution of patients who reached or did not reach MCID ≥ 4 on the DLQI 
after autohemotherapy (a). No significant difference was observed by McNemar test 
(p>0.05). MCID = Minimal clinically important differences. N = 43 
6.2.4 Correlations between UAS7 and DLQI 
Treatment with autologous serum for 8 weeks, UAS7 in week 0, 8, 12 and 20 correlated 
with DLQI values in week 1, 9, 13 and 21, respectively. (Spearman test, p = 0.047, 0.0071, 
0.0006 and ≤ 0.0001) (Figure 6.5 a, b, c, and d)  
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Figure 6.5 Correlations of UAS7 and DLQI at different time points were calculated by 
Spearman test (regression line calculated by Pearson test for better visual understanding). 
UAS7 = Weekly Urticaria Activity Score. DLQI = Dermatology Life Quality Index. N = 41, 
39, 41 and 34 for a, b, c and d, respectively. 
6.2.5 Distribution and kinetics of response 
According to the reduction of UAS7, patients were grouped into complete response (CRs), 
partial response (PRs) and non-response (NRs). At the end of the treatment phase (in 
week 8), the rate of complete response and partial response was 13 % and 48 %, 
respectively. The response rate increases constantly within the 8 weeks of weekly 
treatment and continues to increase after treatment. At the end of the follow up, in week 
20, nearly two-thirds of patients showed complete and partial response to autologous 




Figure 6.6 Distribution of patients with complete, partial and non-response to treatment 
with autologous serum during the treatment phase (week 1-8) and the follow-up period 
(week 12 and week 20). N = 46. 
6.3 Changes in ASST status and clinical response after treatment with 
autohemotherapy 
As part of the inclusion criteria, all patients were tested ASST-positive at baseline (week 
0). After 8 weeks of treatment with autologous serum, 28 % (14/50, p ≤ 0.0001 as 
compared to baseline) of patients were ASST-negative. In week 21, the last week of the 
follow-up period, the rate of ASST negative patients was 34 % (17/50, p ≤ 0.0001 as 
compared to baseline) (Figure 6.7a).  
Each response group (CR, PR, NR) contained patients who turned ASST-negative. There 
was no significant difference comparing complete responders (CRs), partial responders 
(PRs) and non-responders (NRs) for their rates of patients who became ASST-negative 
(Chi-square test, p > 0.05). 40 % (2/5) and 54.5 % (6/11) of CRs, 22.2 % (4/18) and 30.8 % 
(4/13) of PRs, and 26.7 % (4/15) and 21.4 % (3/14) of NRs were ASST-negative at week 
9 and week 21, respectively (Figure 6.7b). There was also no significant difference when 
comparing patients who became ASST-negative with patients who remained ASST-
positive for their rates of CR, PR and NR (Figure 6.7c).  
 
In addition, patients who experienced significant quality of life (QoL) improvement (MCID 
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≥ 4) did not show different rates of turning ASST-negative than those who did not improve 
in their QoL (MCID < 4). Also, patients who showed a change in their ASST status did not 






Figure 6.7 Comparison of changes in ASST (a) and proportions of ASST positive and 
negative patients in complete, partial and non-responders at week 9 and 21 (b and c). At 
baseline (week 0), all patients were ASST-positive. *** p ≤ 0.001, **** p ≤ 0.0001 
(McNemar test). ASST +/- = Autologous Serum Test Positive/ Negative. CR = Complete 
response, PR = Partial response, NR = Non response. N = 50, 38 and 38 in Figure a, b 
and c respectively.  
6.4 Response to treatment and changes in BHRA  
Before the start of autohemotherapy, 5 of 41 patients were BHRA-positive, and these 5 
patients were similar in their treatment responses as compared to BHRA-negative 
patients. After 8 weeks of weekly treatment with autologous serum injections, 4 of the 5 
BHRA-positive remained BHRA-positive, and the one patient who became BHRA-
negative was a non-responder and did not achieve a significant QoL improvement in week 
9. There was no significant difference in the rate of patients who were BHRA-positive 
before and after the therapy (McNemar test, p>0.05) (Figure 6.8). In addition, no link was 
observed between the changes in ASST and BHRA (Chi-squared test). There was no 
difference found between the clinical responses with BHRA status (Mann Whitney U test, 
p>0.05). 
 
Figure 6.8 The histamine release of basophils by the serum of the patients as assessed 
at week 0 and week 9. Positive or negative BHRA was defined by a cut-off value of 16.5 %. 
No significant difference was observed by McNemar test (p>0.05). BHRA +/- = BHRA 
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positive/negative. BHRA = Basophil histamine release assay. N = 41;  
6.5 Changes in the concentrations of IgE-anti-IL-24 and IgG-anti-IL-24 
6.5.1 Serum concentrations of IgE-anti-IL-24 were reduced by treatment, but IgG-
anti-IL-24 were not 
Therapy with autologous serum reduced the serum concentrations of IgE-anti-IL-24 by 
18% and 22%, from 161,457 ± 14,294 counts (before treatment) to 133,024 ± 17,455 
counts (at week 9, p ≤ 0.001) and 126,355 ± 13,431 counts (at week 21, p ≤ 0.001), 
respectively (Figure 6.9a). In contrast, serum concentrations of IgG-anti-IL-24 did not 
change significantly (p > 0.05, Figure 6.9b). 
 
 
Figure 6.9 Comparison of IgE-anti-IL-24 and IgG-anti-IL-24 concentrations at different 
time points during treatment with autologous serum. The serum concentrations of IgE-
anti-IL-24 and IgG-anti-IL-24 were measured via ELISA. Data is displayed as mean and 
standard deviation (SD). IL-24 = Interleukin 24.  ** P ≤ 0.01, ***P ≤ 0.001(Wilcoxon 
signed-rank test); N = 15. 
6.5.2 Correlations between the concentrations of IgE-anti-IL-24 and IgG-anti-IL-
24 
As shown above, autohemotherapy reduced the serum concentrations of IgE-anti-IL-24 
and IgG-anti-IL-24. Figure 6.10 indicated the correlation between these two parameters 
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at each time point (Spearman test, regression line calculated by Pearson test for better 
visual understanding). The link between the concentrations of IgE and IgG antibody 
against IL-24 was observed in week 0 (Figure 6.10 a, p=0.02). However, there were no 
correlations found at other time points. 
 
Figure 6.10 Correlations of IgE-anti-IL-24 and IgG-anti-IL-24 concentrations at different 
time points in treatment with autologous serum. The serum concentrations of IgE-anti-IL-
24 and IgG-anti-IL-24 are measured via ELISA. Data are displayed as mean and standard 
deviation (SD). N = 24, 25, 50 and 47 for a, b, c and d, respectively. 
6.5.3 Correlations between UAS7, DLQI and IgE-anti-IL-24 and IgG-anti-IL-24 
concentrations 
After therapy with autohemotherapy for 8 weeks, the concentrations of IgE-anti-IL-24 in 
week 21 strongly correlated, with both UAS7 and DLQI nicely reflecting clinical responses. 
Inverse results were observed in IgG-anti-IL-24, the concentrations of IgG-anti-IL-24 in 
week 9 showed links to UAS7 and DLQI at the same time point (Spearman test, p < 0.05). 
These results may indicate that the concentrations of IgE-anti-IL-24 can reflect the clinical 
response assessed by UAS7 and DLQI at the end of the follow-up period, and 
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concentrations of IgG-anti-IL-24 can indicate the treatment effect after 8-week injections 
with the autologous serum. (Figure 6.11 a, b, c and d). 
After 8 weeks of treatment, there were high initial IgE-anti-IL-24 mean concentrations, 
positively correlated with the clinical response to autohemotherapy, suggesting that high 
concentrations of IgE- anti-IL-24 may predict beneficial response to autohemotherapy 





Figure 6.11 Correlation between the mean concentrations of IgE-anti-IL-24/IgG-anti-IL-
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24 with UAS7 and DLQI (a, b, c and d). Correlation is determined by Spearman test (p < 
0.05, regression line calculated by Pearson test for better visual understanding). The 
correlation of initial mean concentrations of IgE-anti-IL-24 and the response category (e). 
The initial mean concentrations of IgE-anti-IL-24 are the concentrations before treatment 
with autologous serum. The serum concentrations of IgE-anti-IL-24 (a, b, e) and IgG-anti-
IL-24 (c, d) were measured via ELISA. Data is displayed as mean and standard deviation 
(SD). N = 39,37,19,15 and 12 in a, b, c, d and e, respectively. 
6.5.4 The reduction of IgE-anti-IL-24 linked to the response to treatment 
In different response groups, the mean concentrations of IgE-anti-IL-24 and IgG-anti-IL-
24 all declined after treatment at week 9 (IgE-anti-IL-24: 158,821 ± 14,840 counts to 
133,916 ± 11,586 counts in complete response and partial response; 158,884 ± 12,398 
counts to 132,348 ± 24,717 counts in non response. IgG-anti-IL-24: 153,550 ± 24,230 
counts to 148,372 ± 24,876 counts in complete response and partial response; 148,404 
± 14,979 counts to 143,418 ± 18,453 counts in non response) (Figure 6.12). In complete 
and partial responders to autohemotherapy, but not in non-responders, the mean 
concentrations of IgE-anti-IL-24 declined significantly from week 0 to week 9 (p ≤ 0.05) 
(Figure 6.12 a). 
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Figure 6.12 Comparison of IgE-anti-IL-24 and IgG-anti-IL-24 serum concentrations in 
different response groups before and after treatment. Data is displayed as mean and 
standard deviation (SD). Data shown are from all patients with available data at the 
specific time points. Statistical comparisons were done only for paired data available at 
baseline (week 0) and post treatment (week 9 or week 21). * P ≤ 0.05(Wilcoxon signed-
rank test). N = 9, 5, 9 and 5 for a, b, c, and d, respectively;  
6.5.5  No link between the reduction of IgE-anti-IL-24 and ASST changes 
In week 9 and week 21, some patients turned ASST-negative after the treatment and at 
the end of the follow-up period. There were no differences in serum concentrations of 
IgE-anti-IL-24 or IgG-anti-IL-24 in patients who became ASST-negative or not at any time 
point after autohemotherapy (Figure 6.13). 
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Figure 6.13 Comparison of IgE-anti-IL-24 and IgG-anti-IL-24 serum concentrations 
patients who become ASST negative with patients who remain ASST positive after 
treatment. Data are tested by Mann-Whitney U test and displayed as mean and standard 








The main aim of this thesis was to explore the immunological effects and the potential 
mechanisms of action of autohemotherapy in CSU. Our findings confirm that autologous 
serum therapy has sustained clinical effects on ASST-positive CSU patients and highly 
suggests that autohemotherapy can induce changes in immunological mechanisms 
including a reduction of skin reactivity to serum factors and concentrations of 
autoantibodies. The mean concentrations of IgE-anti-IL-24 show a correlation with both 
UAS7 and the DLQI at week 21 Furthermore, the initial high concentrations of IgE anti-
IL-24 of CSU patients could be possibly utilized to predict a positive treatment response 
to autohemotherapy. 
7.1 Effects of autohemotherapy in ASST- positive CSU patients 
CSU is frustrating for both physicians and patients. It not only reduces the patients’ quality 
of life, but also affects their performance at work and school. The quality of life impairment 
of a CSU patient is comparable to that of a patient suffering from coronary artery disease 
reported by O’ Donnell et al. (1997)98. CSU is a mast cell-mediated disease, in which 
mast cells can release histamine and other mediators, such as prostaglandin D2 (PGD2), 
TNF and cytokines. To date, many efforts have been made to identify the causes of CSU, 
but the pathomechanisms of CSU are still not fully understood. Two types of autoimmune 
mechanisms are held to be relevant in the pathogenesis of CSU patients: Type I 
autoimmunity (also called autoallergy) with IgE autoantibodies to autoantigens and Type 
II autoimmunity with IgG autoantibodies to IgE or its high affinity receptor, FcɛRI54. As first 
described by Rosman et al. in 196255, CSU could be caused by a hypersensitivity type I 
reaction in which antigens crosslink IgE molecules on mast cells and basophils resulting 
in the release of histamine and other pro-inflammatory mediators. There is evidence that 
autoimmune CSU patients have significantly higher concentrations of IgE autoantibodies 
against double-stranded DNA and thyroid antigens such as thyroid peroxidase / 
thyroglobulin than normal subjects48,56,57.  
Autohemotherapy has been reported for over 100 years to treat various diseases 
including allergic rhinitis, atopic dermatitis, asthma, viral diseases and chronic 
urticaria82,94-97. It was firstly used for several dermatologic conditions by Ravaut (1913)103 
and Spiethoff (1913)104. However, after several decades, autohemotherapy was largely 
abandoned due to a lack of evidence and fear of side effects such as transmitting blood-
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borne pathogens. Furthermore, some studies found soreness and/or bruising at the 
injection site, especially with autologous whole blood105. In the past few years, several 
researchers have started to rebuild the knowledge of autohemotherapy in the treatment 
of dermatologic diseases including urticaria with systematic and rigorous studies. 
Moreover, in a recent review by Brewer90, autohemotherapy was not shown to cause 
major side effects.  
In our study, 66 ASST-positive CSU patients were recruited to receive autohemotherapy. 
The first UAS7 score was measured before the treatment. In a recent review by Brewer 
(2014)90 no association between the baseline symptom severity and the response to 
autohemotherapy was shown in the comparison of different studies. In our study, 
autohemotherapy reduced disease activity by 36 % after 8 weekly injections, led to 
sustained benefit at week 20 (46% reduction), and improved disease activity as early as 
after the second injection of autologous serum (see Figure 6.1). Also, the on-demand 
antihistamine consumption was significantly decreased by more than 50% as compared 
to baseline (see Figure 6.2). The results are in line with studies of Majid et al. (2015)106 
that showed a dramatic decline during the first few injections. Moreover, the scores were 
constantly decreased at week 20 (p ≤ 0.0001), which indicates that autologous serum 
therapy can induce rapid and stable effects in CSU patients. Nearly two-thirds of all 
patients showed complete and partial response at the end of the follow-up period (see 
Figure 6.6). In this regard, our findings are completely in agreement with previous studies 
by Chen et al. (2012)107, Godse et al. (2017)80 and Abdallah et al. (2012)105. Abdallah et 
al. (2012)105 performed a study to compare the efficacy of autologous whole blood 
injections and autologous serum injections among ASST-positive patients and found both 
modalities were equally effective. They observed that autohemotherapy reduced the pill 
burden and improved the quality of life. Chen et al. (2012)107 found a 50 % reduction of 
UAS7 from baseline to the end of follow-up after autohemotherapy. Godse et al. (2017)80 
compared the effects of subcutaneous injections of autologous serum and saline control 
in treatment of CSU and suggested that subcutaneous autologous serum therapy 
significantly reduced the disease activity assessed by UAS7 and the requirement of 
antihistamines. More recently, Staubach et al. (2006)82 and Elazab et al. (2017)83 
revealed that autohemotherapy could be very effective in autoimmune CSU patients, 
because ASST-positive showed a better clinical response than the ASST-negative control 
group in both studies. 
CSU is known to have a substantial impact on patients’ quality of life. In our study, the 
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quality of life of our patients was improved after the last autologous serum injection and 
further improved thereafter (see Figure 6.3). One in three patients and almost 50% of 
patients experienced significant quality of life improvement, i.e. a reduction of the DLQI 
by the minimal clinically important difference of 4 points, by the end of the treatment and 
follow up phase, respectively (see Figure 6.4). These results confirm the findings of an 
earlier study by Panchami et al. (2014)108.  
Comparing the duration of the treatment and follow-up period with the previous 7 
studies51,81,82,99,105,107,109, we chose the treatment length of 8 weeks (average treatment 
length was 8.7 weeks (from 5 weeks to 12 weeks)) and follow-up for 12 weeks (average 
follow-up period was 7.4 weeks (from 4 weeks to 16 weeks)). The frequencies of 
injections were all reported to be once per week. 
In CSU, both UAS7 and DLQI are different measurements and critical factors to analyse 
the effects and impairment of the disease for patients. The improvement of disease 
activity and DLQI strongly correlated at each corresponding time point in our study. The 
good correlation between UAS7 and DLQI observed suggested robustness in our data. 
The combination of these two parameters enables better insight into the impact of the 
disease on social and everyday activities. Both of them are valuable instruments in 
measuring response to treatment (see Figure 6.5).  
A minimal clinically important difference (MCID) of 4 points has been estimated for DLQI 
in CSU patients to be important for treatment decisions. The changes in MCID ≥ 4 mean 
that the patient experiences a meaningful change in QoL. We found that the proportion 
of patients that reached a MCID of ≥ 4 at week 9 and week 21 was 35 % and 47 %, 
respectively (see Figure 6.4). These results are also in line with the studies of Panchami 
et al. (2014)108, who reported that the autologous serum therapy significantly improved 
UAS7 and DLQI from baseline. In contrast, a placebo controlled, randomized, single-blind 
study with CSU patients carried out by Kocatürk et al. (2012)51 underlined that autologous 
whole blood injections and autologous serum injections are equally effective as placebo 
injections in reducing disease activity. To analyse the reason for symptom improvements 
in the placebo patients, they may be due to physiological effects caused by antihistamine 
on demand and psychological impacts90. For example, saline injections may also cause 
an immune response. This hypothesis is consistent with the observation from clinical trials 
with omalizumab that showed placebo injections to induce higher improvement than oral 
placebos in other trials77,106-108. Another reason for the improvement with placebo 
according to Brewer might also be associated with the inclusion of patients who were 
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presumably experiencing peak symptom severity that spontaneously declined during the 
study90.  
Taken together, our results and those of previous studies underline that autohemotherapy 
can have rapid, positive and persistent effects on disease activity and impact in patients 
with CSU, but they do not provide an explanation for why this happens.  
7.2 Changes in ASST status and clinical response after treatment with 
autohemotherapy 
30-50 % of CSU patients express autoantibodies that can induce degranulation of mast 
cells and basophils including circulating autoantibodies directed against the high-affinity 
receptor for IgE (IgG-anti-FcɛRI) or the IgE molecule itself (anti-IgE)113,114. The presence 
of these histamine releasing factors (HRFs) can be confirmed by both in vivo autologous 
serum skin test (ASST) and in vitro basophil histamine release assay (BHRA) 51. After 
comparing the results of the ASST and BHRA, Sabroe et al. (2006) found that 60 % of 
the subjects showed ASST-positive, however, only half of ASST-positive serum activated 
basophils in BHRA. This finding demonstrates that the serum factors in ASST (mast cell 
specific) are different from those in BHRA (anti-IgE or anti-FcεRI)115. Meanwhile, the 
ASST has been proven to be one of the most useful, rapid and reliable clinical tests for 
differentiating between patients with and without circulating functional 
autoantibodies116,117. However, the methodology and the definition of a positive response 
are under debate and it is still unknown whether the injections of autologous serum can 
change the immunologic profiles of CSU patients.  
Some studies showed the skin testing with autologous serum could elicit a wheal and 
flare response in most CSU patients during disease activity but not in the clinical 
remission period49 and suggested the test should be regarded as a test for autoreactivity 
rather than specific test for autoimmune urticaria118. Magen et al. (2012)119 found that the 
standard dose of antihistamines could not inhibit the wheal size induced by the 
intradermal injection of autologous serum in resistant CSU patients. Histology of ASST 
biopsies from CSU patients showed mixed infiltrates of neutrophils, mononuclear cells 
and eosinophils and the electron microscopy showed mast cell degranulation120. However, 
it is still unknown whether the injections of autologous serum can change the autoreactive 
profile of CSU patients. 
Recently, the impact of positive or negative states of ASST on disease activity or 
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treatment decisions in CSU patients was discussed as being a controversial issue. Both 
Staubach et al. (2006)82 and Elazab et al. (2017)83 revealed that the ASST-positive 
patients show better effects to autohemotherapy than the ASST-negative autoimmune 
CSU patients. They proposed a mechanism where circulating histamine-releasing factors 
might induce tolerance. Since we primarily aimed at the mechanisms of action of 
autohemotherapy in CSU, we did not implement a placebo control and concentrated on 
the ASST status and the analysis of parameters in the serum of the patients within the 
treatment period. In Brewer’s systematic review of autohemotherapy, he summarized that 
ASST-positive patients had 19 % less severe urticaria symptoms at the end of follow-up 
than ASST-negative patients in relevant studies90.  
In our study, the ASST became negative in only one third of the treated patients at the 
end of the follow-up phase, and this was not linked to the clinical response of patients. In 
other words, some patients (4/10 at week 9, 3/13 at week 21) without clinical benefit 
became ASST-negative, and some patients (17/28 at week 9, 14/25 at week 21) who had 
clinical benefit remained ASST-positive (see Figure 6.7). The latter has been described 
previously by Mori and Hashimoto121, who reported CSU remission in a ASST-positive 
patient treated with autologous whole blood injections, without changes in the patient’s 
ASST status. Panchami et al. (2014)81 evaluated and compared the effectiveness of 
autologous serum therapy in autoreactive urticaria and non-autoreactive urticaria patients. 
He concluded that autologous serum therapy showed promising effects in both 
autoreactive and non-autoreactive CSU patients, and the effects are shown regardless of 
the presence of autoreactivity. You et al. (2015)122 also demonstrated that antihistamine-
resistant CSU patients did not respond significantly to autohemotherapy in spite of the 
skin test results to autologous serum. The above findings suggest that the status of ASST 
may not reflect the disease activity and the response to autologous hemotherapy in CSU 
patients. 
7.3 Response to treatment and changes in BHRA 
Basophil histamine release assay is a measurement of histamine release from healthy 
donors’ basophils co-incubated with patients’ serum123. It is used to detect functional 
autoantibodies, which have been shown to have good sensitivity and specificity for the 
presence of endogenous histamine-releasing factors124. Only about 50 % of ASST-
positive CSU patients seem to have functional autoantibodies in the basophil assay. 
Bindslev-Jensen et al. (2000)123 recommended that if the examined patients have positive 
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ASST results, the presence of HRFs should be confirmed by basophil histamine release. 
In accordance with those studies, we tested the serum autoreactivity by BHRA. In our 
study, we did not observe significant changes in BHRA response before and after 
autohemotherapy (see Figure 6.8). Moreover, changes in BHRA and ASST reactivity of 
the patients were not linked to the clinical response assessed by UAS7. Although the 
presence of HRFs was suggested to be confirmed by both ASST and BHRA, there was 
no correlation between these two methods in our study. In the study of Platzer et al. (2005), 
they explained the missing correlation between ASST and BHRA by the assumption that 
a low titre of HRFs or ‘mast cell-specific’ HRFs might be present in the serum of CSU 
patients who have a positive ASST but negative BHRA results. On the contrary, the 
results shown with negative ASST and a positive BHRA might be explained by some 
inherent variability of the ASST124. In our study, only one patient became BHRA negative 
and this patient was a non-responder. We did not have access to direct assays for 
measuring the concentrations of IgG autoantibodies and their changes in our patients. 
But even if we had measured antibody concentrations and had found a reduction in 
response to autohemotherapy, this would hardly be relevant pathomechanistically, as 
functional tests such as the ASST and the BHRA remained positive in the majority of 
patients and changes in the results of these functional tests were not linked to treatment 
responses. 
7.4 Changes in the concentrations of IgE autoantibodies against IL-24 after 
autohemotherapy 
Bajaj et al. (2008) and Schmetzer et al. (2018) suggested that CSU is an autoimmune 
disease in which IgE recognizes several autoantigens. IgE against many autoantigens 
was frequently found to be exhibited in CSU patients, while only eight of the autoantigens 
against IgE expressed symptoms in the skin, and only IgE autoantibodies against 
interleukin 24 (IL-24) were detectable in all CSU patients. IL-24 has been identified as a 
common, specific and functional autoantigen of IgE autoantibodies in CSU. Also, IgE-
anti-IL-24 could not be detected in patients with idiopathic anaphylaxis or healthy subjects, 
rather only in patients with CSU. Here, the concentrations of IgE-anti-IL-24 were 
associated with the disease activity68. Based on this data, we especially analysed 
changes of IgE-anti-IL-24, as it seems to be a good candidate to observe concentrations 
and changes of IgE autoantibodies over time in CSU patients.  
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In this work, we measured the serum concentrations of IgE-anti-IL-24 by ELISA. Our 
results showed a significant reduction in the mean concentrations of IgE-anti-IL-24 after 
8-week injections with autologous serum and the concentrations continually decreased 
till the end of follow-up period (see Figure 6.9a). This indicates that autohemotherapy 
has a significant effect on changing the concentrations of these autoantibodies. Based 
on these results, we further used the same ELISA protocol to measure the IgG antibody 
against IL-24 (see Figure 6.9b). Unlike the decrease in IgE-anti-IL-24 serum 
concentrations, the IgG-anti-IL-24 only displayed fluctuant changes and there were no 
remarkable changes observed at different time points.  
In the results of IgE-anti-IL-24 serum concentrations, we also detected a correlation 
between concentrations of IgE-anti-IL-24 and clinical response as assessed by UAS7 and 
DLQI at the end of the follow-up period (see Figure 6.11). This is in agreement with 
results from the study of Schmetzer et al. (2018)68. The correlation between the clinical 
response at week 8 and the initial concentrations of IgE-anti-IL-24 in the patient group of 
Berlin (see Figure 6.11e) indicates that high initial concentrations of IgE-anti-IL-24 before 
treatment might predict a treatment response to autohemotherapy in CSU, which 
emphasizes the initial concentrations of IgE-anti-IL-24 as a potential prognostic marker. 
From the above findings, we considered that these different parameters may be used not 
only to predict the clinical response to autohemotherapy, but also to evaluate the 
therapeutic effects.  
7.5 Proposed mechanisms of autohemotherapy 
How does autohemotherapy work in CSU? Our hypothesis was that autohemotherapy, in 
patients who benefit from this treatment, reduces the concentrations and/or effects of 
these mast cell-degranulating IgE and IgG autoantibodies. Our results strongly suggest 
that autohemotherapy reduces the concentrations of IgE autoantibodies, but not the 
concentrations or effects of IgG autoantibodies. 
The mechanism of action of autohemotherapy has not yet been well understood and only 
a few studies and hypotheses about potential mechanisms of autohemotherapy have 
been published so far. Some authors suggested that autohemotherapy could prompt the 
tolerization of patients to autoantigens in the blood circulation. For example, Alvarado-
Flores et al. (2001)125 indicated that there were tolerance-generating anti-idiotype 
antibodies to mast cell degranulation presented in autologous serum as assessed in 
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various autoimmune diseases.  
Other researchers measured the changes in cytokines after injections of autologous 
serum, e.g., Liang et al. (2012)126. They treated 24 allergic rhinitis patients with 
acupuncture autohemotherapy while 21 patients were treated with western medications 
for 3 months for comparison. They measured their serum levels of interferon-gamma 
(IFN-gamma) and interleukin 12 (IL-12). The results showed that the therapy significantly 
relieved the clinical symptoms and the symptom relief correlated with the increase of IL-
12 and IFN-gamma. Zhang et al. (2014)88 demonstrated that the mechanism of action of 
autohemotherapy is related to the downregulation of IL-4 and total IgE in CSU patients.  
Our results do suggest that autohemotherapy works in CSU, at least in part, because of 
its effects on IgE autoantibodies. First, we found that our patients treated with 
autohemotherapy showed a significant reduction of their IgE-anti-IL-24 concentrations 
after 8 weekly injections with autologous serum, and their concentrations continued to 
drop thereafter. Second, the drop in IgE-anti-IL-24 was only significant in responders, but 
not in non-responders to autohemotherapy although statistical comparisons in the 
analysis are based on small patient numbers in each response group. Taken together, 
these findings support the idea that IgE-autoantibodies such as IgE-anti-IL-24 are one of 
the targets of the mechanisms of action of autohemotherapy in CSU. 
7.6 Limitations 
Our study has several important strengths and limitations, and it points to interesting 
questions that need to be addressed by further studies. The limitations of our study 
include its uncontrolled design and relatively small sample size. Besides, the incomplete 
data sets with many missing values for certain time points and analyses may reduce the 
study quality and reproducibility, and may cause a risk of bias. In retrospect, we should 
not have limited inclusion into the study to ASST-positive patients. ASST positivity of our 
patient population, has undoubtedly biased our study group towards type IIb autoimmune 
CSU and against type I autoimmune CSU, in which autohemotherapy now has to be 
expected to be more effective than in type IIb autoimmune CSU. On the plus side, our 
patient population was fairly homogeneous, it was a multicenter study, and our key 
outcomes included major pathogenic drivers of type I and type IIb autoimmune CSU. 
Further studies are needed to better characterize the relevance and mechanisms of these 
effects of autohemotherapy. How is IgE-anti-IL-24 reduced by autohemotherapy: by 
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effects on its production, its clearance, or both? Are other IgE autoantibodies and 
concentrations of total IgE also reduced by autohemotherapy in CSU patients, ASST-
positive and ASST-negative patients? Are total IgE concentrations affected by 
autohemotherapy? 
7.7 Conclusion and outlook 
In summary, our study demonstrates that autohemotherapy can lead to clinical benefit in 
part by its effects on concentrations of IgE autoantibodies against IL-24 in ASST-
positive CSU patients. This supports the notion that specific and functional IgE 
autoantibodies contribute to the pathogenesis of CSU and suggests that these IgE 
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Table A.2 Dermatology life quality index 
 
 
Centre Nr.:  |__|__|__|  Date: |__|__|__|  
Patient Nr.:  |__|__|__|  T / M / J 
Patients Initials |__|__|__|  Diagnose : ____________ 
The aim of this questionnaire is to measure how much your skin problem has 
affected your life OVER THE LAST WEEK. Please tick one box for each question. 
1.  Over the last week, how itchy, sore, 
painful or stinging has your skin 
been? 
Very much  
A lot 
A little 






2.  Over the last week, how 
embarrassed or self-conscious 
have you been because of your skin?  
Very much  
A lot 
A little 








3.  Over the last week, how much has 
your skin interfered with you going 
shopping or looking after your home 
or garden?  
Very much  
A lot 
A little 








Not relevent   
4.  Over the last week, how much has 
your skin influenced the clothes you 
wear?  
 
Very much  
A lot 
A little 








Not relevent   
5.  Over the last week, how much has 
your skin affected any social or 
leisure activities?  
Very much  
A lot 
A little 













Over the last week, how much has 
your skin made it difficult for you to do 
any sport?  
Very much  
A lot 
A little 








Not relevent   
	Score DLQI 
	 67	
7.  Over the last week, has your skin 







Not relevent   
 If "No", over the last week how much 










8.  Over the last week, how much has 
your skin created problems with your 
partner or any of your close friends 
or relatives?  
 
Very much  
A lot 
A little 








Not relevent   
9.  Over the last week, how much has 
your skin caused any sexual 
difficulties?  
  
Very much  
A lot 
A little 








Not relevent   
10. Over the last week, how much of a 
problem has the treatment for your 
skin been, for example by making 
your home messy, or by taking up 
time?  
Very much  
A lot 
A little 








Not relevent   
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